The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looking promising, boom.
Did say I suspected something going on in the background with steady new buys......perhaps this is the first RNS of many over the coming weeks!
So lumsden FINALLY steps down as CEO and they suddenly have enough cash to last the extra month. Says it all. He should be frogmarched to the bank and forced to hand his salary from the last yr back to the CFO.
Has there ever been a CEO even on AIM that has overseen such destruction of shareholder value without so much as an acknowledgement of his failings?
Let's see what this new guy Chris Wardhaugh can do.!Sounds far better to suited to the task at hand. I had zero confidence in lumsden salvaging anything other than his own paycheck so today's update is very weclome indeed.
There may be some hope yet that they can do sthg with this ticker, whether it be a TO or RTO. Plenty of tax credits to sweeten the deal. Also, surely iclaprim has some value?
GLA.
Looks like a dead cert with Lamellar's Chris Wardhaugh appointed as a Non-Executive Director of MTFB;
If Iclaprim is the main compound in Lamellar's LAMELLASOMEâ„¢ nebulised formulation treatment believed to have inherent attributes that are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients, then presumably because Iclaprim has already been cleared in Phase 11 patient trials, then Lamellar's technology and formulation could go straight into CV patient trials. This would be highly significant and make Lamellar the most likely RTO target and transformational for all invested, with the prospect of Lamellar's inhaler technology reaching CV patients immediately , and then potentially scaled up for commercialisation on positive trials, and if this is the case then this would be absolutely huge and maybe the multi-bags of all multi-bags from current rockbottom sp... Gla !!! ;-)
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME™ Technology
....................
A LAMELLASOME™ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in-vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOME™ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOME™ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
https://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using
1/5/19
Motif Bio Signs Agreement with Lamellar Biomedical
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.
Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.
The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.
Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."
Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."
24/10/19
RNS Number: 9200Q Motif Bio PLC, 24 October 2019
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
htTps://adisinsight.springer.com/drugs/800018080
6/6/19
"We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with ABSSSI and potentially also in patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia. In addition, we are exploring the use of iclaprim in other disease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.
The Company's Directors remain focused on sourcing an appropriate reverse takeover candidate for Motif Bio. The Company is required to make an acquisition which constitutes a reverse takeover under the AIM Rules by 28 July 2020, failing which the Company's ordinary shares would be suspended from trading on AIM pursuant to AIM Rule 40. The Company's admission to trading on AIM would then be cancelled six months from the date of suspension, should the reason for the suspension not have been rectified. At present, no assurances can be given that the efforts to source and/or complete a reverse takeover transaction will be successful.
The following information is disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:
Christopher Thomas Wardhaugh, aged 50, holds or has held the following directorships or partnerships in the past five years:
Current Directorships or Partnerships
Previous Directorships or Partnerships
Altair Medical
Clyde Biosciences
Lamellar Biomedical
Sercader Limited
Chris currently holds no interest in the ordinary share capital, or other securities, of Motif Bio.
Here's confirmation of the Lamellar connection. Gla ;-)
RNS Number : 7166L
Motif Bio PLC
04 May 2020
Directorate Changes & Corporate Update
Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces the following changes to the Board, with immediate effect:
- Chris Wardhaugh is appointed as a Non-Executive Director;
- Jonathan Gold, the Company's current Chief Financial Officer ('CFO'), has been appointed as President and Chief Business Officer;
- Graham Lumsden, the Company's Chief Executive Officer ('CEO'), will step down from his role as CEO and become a Non-Executive Director; and
- Bruce Williams continues in his role as Chairman.
Christopher (Chris) Wardhaugh
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.
Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.
Commenting, Bruce Williams, Chairman of Motif Bio, said: "We welcome Chris to the Board as we focus on sourcing an appropriate reverse takeover candidate for Motif Bio. We believe that the Company will benefit from Chris's breadth of knowledge and transactional experience and we will provide shareholders with further updates in due course."
Jonathan Gold
Jonathan Gold is appointed President and Chief Business Officer, an expanded role that includes his previous responsibilities as CFO.
Graham Lumsden
Graham has stepped down from his role as CEO, a role he has had since the Company's IPO in 2015. Graham will continue to support the Company as a Non-Executive Director.
Current Financial Position
The Directors of Motif Bio have continued to impose disciplined cost controls, with the Company maintaining very limited operations. As a result, Motif Bio's cash balance is approximately £0.23 million as at 4 May 2020, which has allowed the Company's cash runway to be extended into June.
Was this your last nights dream
Interest in "company" given management zero, though IP is a different matter.
Found this,
In addition, preclinical and clinical data suggest that the antibiotic azithromycin (Zithromax®, Pfizer Inc., New York, NY, USA) has antiviral properties and this is expected to be investigated in patients with COVID-19 in the near future.7
Maybe someone could be interested in this company.
Yes interesting isn’t it!
Interesting to see some moves regarding covid 19 respiratory treatment. Interesting times folks.
Doing secondary school work oh how I still love Maths and Science although I am getting an education this time around. Hope all is well with you and everyone on here’s family’s. I can’t wait till end of May when my paper loss bears fruit( sort of ) lol.
Thanks Kettle, You probably didn't mean it as such but I took that as a complement. I have never even been called slightly subtle before. I trust that you and yours are staying safe and well.
But far more subtle than yours Lawson. Lol
I came across an american promoter
,saying that there is a tiny company with the most powerful antibiotic that the army have spent 15 million on and does not need phase2 trials.
I never paid for the end of the promotion but sounds familiar eh! Let's hope watch this space.
And I thought that I wrote the most pointless posts!!!
“Motif Bio's cash balance was approximately £0.25 million as at 14 April 2020 and with outstanding and expected near term obligations the Company currently has sufficient working capital into May 2020.”
We go “into” May Friday.
I've been dipping in and out of Motif for the past couple of weeks. Worth a punt for quick returns. Done a few hundred quid a day most days. It's great as the spread is usually tight so quick returns, and constantly up and down ??
Thank’s for reply. But it is still strang for me, why one should do it ! :)
24-Apr-20 15:40:06 0.20518 239,791 Buy* 492.00 O
24-Apr-20 15:37:31 0.20518 239,791 Buy* 492.00 O
24-Apr-20 15:23:05 0.22 223,638 Buy* 492.00 O
24-Apr-20 15:16:59 0.22 223,638 Buy* 492.00 O
24-Apr-20 11:20:56 0.22833 215,479 Buy* 492.00 O
23-Apr-20 16:22:53 0.2295 650,000 Buy* 1,492 A
23-Apr-20 16:09:22 0.22849 215,328 Buy* 492.00 O
23-Apr-20 16:04:41 0.22849 215,328 Buy* 492.00 O
23-Apr-20 12:43:32 0.2192 1,000,000 Buy* 2,192 O
Looking at the above trades, these could be all be buys from the same person. See how the bought value is £xx92 (where the x is either 4, 14 or 21)?
When buying shares most people select the number of shares they want and the final price ends up being a random cost like £581.51, especially with low value shares. It looks like this purchaser wants to buy whatever amount of shares they can get for a fixed price, eg £492. Would several random people decide to buy MTFB shares on the same day and decide they wanted to buy them for a fixed price of £xx92 ?
If these were all bought by the same person that is 3,222,993 shares they have quietly bought over the course of 1.5 days. This is as far back as the recent trades page shows so I don't know if they have been doing it regularly since the 14th of April.
Morten28: I'm not sure who could be buying but somebody is quietly accumulating. Look at the buys on Friday and you'll see somebody is buying shares in £492 chunks throughout the day. There have been the same pattern of buys where it looks like the same person is buying small quantities of shares several times rather than drawing attention to themselves and buying over 1m shares at a time (maybe they get an NT asking for larger quantities or they want to buy in without driving the price up).
I can’t understand. Why is there still action ? Who buy the shares ?
Loki- I hope you re-think your strategy over this weekend. If you can still get 700 quid back, then do it. There are many who have lost 20 or 30 times what you will (ST. Valentine's Massacre in 2019). You got played. Move on; you will get over it. If it seems too good to be true, it probably is. I lost about 4k on this turd (bought in AFTER the above-mentioned massacre, and believed the CEO ("We do not believe there needs to be an additional trial").....